The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds
Open accessAbstract
Natural product drug discovery has regained interest due to low production costs, structural diversity, and multiple uses of active compounds to treat various diseases. Attention has been directed towards medicinal plants as these plants have been traditionally used for generations to treat symptoms of numerous diseases. It is established that plants harbour microorganisms, collectively known as endophytes. Exploring the as-yet untapped natural products from the endophytes increases the chances of finding novel compounds. The concept of natural products targeting microbial pathogens has been applied to isolate novel antimycobacterial compounds, and the rapid development of drug-resistant Mycobacterium tuberculosis has significantly increased the need for new treatments against this pathogen. It remains important to continuously screen for novel compounds from natural sources, particularly from rarely encountered microorganisms, such as the endophytes. This review focuses on bioprospecting for polyketides and small peptides exhibiting antituberculosis activity, although current treatments against tuberculosis are described. It is established that natural products from these structure classes are often biosynthesised by microorganisms. Therefore it is hypothesised that some bioactive polyketides and peptides originally isolated from plants are in fact produced by their endophytes. This is of interest for further endophyte natural product investigations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Biodiversity hotspots for conservation priorities
Myers, N., Mittermeier, R. A., Mittermeier, C. G., da Fonseca, G. A. B., & Kent, J. (2000) · Nature · doi:10.1038/35002501 · Cited by 31,710
Natural products as sources of new drugs over the 30 years from 1981 to 2010
Newman, D. J., & Cragg, G. M. (2012) · Journal of Natural Products · doi:10.1021/np200906s · Cited by 4,687
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 1×
“Drug Sponsor Class In vitro potency Mode of action Clinical trial status TMC 207 (Bedaquiline) Janssen Diarylquinoline 30–120 ng/ml (Andries et al., 2005; Koul et al., 2008) Targeting ATP synthase, inhibition of proton pumping activity (Huitric et al., 2010) III, FDA-approved (accelerated…”
A model for the lowering of plant ethylene concentrations by plant growth-promoting bacteria
Glick, B. R., Penrose, D. M., & Li, J. (1998) · Journal of Theoretical Biology · doi:10.1006/jtbi.1997.0532 · Cited by 1,466
inhA , a Gene Encoding a Target for Isoniazid and Ethionamide in Mycobacterium tuberculosis
Banerjee, A., Dubnau, E., Quemard, A., Balasubramanian, V., Um, K. S., Wilson, T., Collins, D., de Lisle, G., & Jacobs, W. R. (1994) · Science · doi:10.1126/science.8284673 · Cited by 1,389
The catalase—peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis
Zhang, Y., Heym, B., Allen, B., Young, D., & Cole, S. (1992) · Nature · doi:10.1038/358591a0 · Cited by 1,299
Wolucka, B. A., McNeil, M. R., de Hoffmann, E., Chojnacki, T., & Brennan, P. J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31657-5 · Cited by 272
Approval of Novel TB Drug Celebrated—With Restraint
Cohen, J. (2013) · Science · doi:10.1126/science.339.6116.130 · Cited by 166 · cited 4×
“From these new rug candidates, the semi-synthetic TMC207 has received FDA pproval, specifically for patients with MDR-TB, through its accelerted approval programme which based its decision on Phase II trials Cohen, 2013; Diacon et al., 2009, 2012).”
BackgroundInfluentialYano, T., Li, L.-S., Weinstein, E., Teh, J.-S., & Rubin, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m508844200 · Cited by 150
Cited by
Plant beneficial endophytic bacteria: Mechanisms, diversity, host range and genetic determinants
Afzal, I., Shinwari, Z. K., Sikandar, S., & Shahzad, S. (2019) · Microbiological Research · doi:10.1016/j.micres.2019.02.001 · Cited by 1,010
Endophytes: A Treasure House of Bioactive Compounds of Medicinal Importance
Gouda, S., Das, G., Sen, S. K., Shin, H.-S., & Patra, J. K. (2016) · Frontiers in Microbiology · doi:10.3389/fmicb.2016.01538 · Cited by 869
Anand, U., Jacobo-Herrera, N., Altemimi, A., & Lakhssassi, N. (2019) · Metabolites · doi:10.3390/metabo9110258 · Cited by 867
Beneficial role of bacterial endophytes in heavy metal phytoremediation
Ma, Y., Rajkumar, M., Zhang, C., & Freitas, H. (2016) · Journal of Environmental Management · doi:10.1016/j.jenvman.2016.02.047 · Cited by 684
A critical review on exploiting the pharmaceutical potential of plant endophytic fungi
Gupta, S., Chaturvedi, P., Kulkarni, M. G., & Van Staden, J. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.107462 · Cited by 346
Metadata
- Authors
- Alvin, A., Miller, K. I., & Neilan, B. A.
- Venue
- Microbiological Research
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 169
- Issue
- 7-8
- Pages
- 483-495
- ISSN
- 0944-5013 (ISSN-L)
- OpenAlex
- W2061043967
- Cited by
- 373
- References
- 9
- FWCI
- 12.55
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds. https://app.cochat.ai/papers/10.1016/j.micres.2013.12.009
- The paper
- Alvin, A., Miller, K. I., & Neilan, B. A. (2014). Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds. Microbiological Research. https://doi.org/10.1016/j.micres.2013.12.009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.